bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

NCT06061276 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Liver Diseases
Hepatocellular Carcinoma
Immunotherapy
Camrelizumab
Lenvatinib

Interventions

PROCEDURE: bTAE-HAIC
DRUG: Lenvatinib
DRUG: Camrelizumab

Sponsor

Sun Yat-sen University